ANGLE PLC S/ADR - ANPCY STOCK NEWS

ANGLE plc has announced a contract with Crescendo Biologics to utilize its Portrait Flex Assay in Crescendo's ongoing Phase 1 clinical trial for CB307, a drug targeting prostate cancer. The assay, developed for detecting circulating tumor cells (CTCs), boasts over 90% sensitivity and specificity, crucial for identifying druggable targets in cancer treatment. Crescendo will process patient samples using ANGLE's Parsortix system at its accredited laboratories. Both companies express enthusiasm about the collaboration, indicating potential for future partnerships. This contract highlights the growing importance of CTC biomarkers in clinical trials, giving ANGLE a stronger foothold in the immuno-oncology sector.

ANGLE plc (OTCQX:ANPCY) will release its preliminary results for the year ended 31 December 2022 on April 21, 2023. A virtual meeting for analysts is scheduled at 10:00 am BST on the same day, with registration required in advance. The company's liquid biopsy technology, notably the Parsortix system, is FDA cleared for use in metastatic breast cancer, serving as the first approved medical device to harvest intact circulating cancer cells from blood. ANGLE aims to enhance cancer diagnostics, supported by extensive clinical studies and collaborations with leading cancer centers.

ANGLE plc (OTCQX:ANPCY), a leader in liquid biopsy, announced on March 10, 2023, the approval of share options under its Remuneration Policy. The Remuneration Committee granted up to 6,000,000 LTIP options to executive directors and up to 9,000,000 Staff Share Options to employees. Following this issuance, total options outstanding will amount to 41,133,147 shares, equating to approximately 13.6% of the issued share capital. The exercise price for Staff Share Options is £0.2575. The LTIP options will vest based on performance conditions related to share price growth over three years, designed to enhance shareholder value.

ANGLE plc reported a significant change in voting rights as Global Frontier Partners, LP acquired an additional stake in the company. The acquisition increased their voting rights from 3.65% to 5.32%, totaling 13,868,946 shares. This threshold was reached on March 7, 2023, with the notification sent on March 8, 2023. Global Frontier Investments, LLC serves as the general partner for the acquired shares, impacting the control dynamics within the company. The increase in holdings signifies a noteworthy investment in ANGLE plc, which could influence future strategic decisions and shareholder value.

ANGLE plc (AIM:AGL, OTCQX:ANPCY) announced key share transactions on February 9, 2023. CEO Andrew Newland purchased 125,000 ordinary shares at 28.75 pence each, signaling confidence in the company’s prospects. Finance Director Ian Griffiths acquired 30,000 shares via his self-invested personal pension (SIPP) at 29.175 pence each. He also sold and repurchased 37,500 shares in his personal account at prices of 29.25 and 29.50 pence, respectively. These transactions were conducted on the London Stock Exchange, reflecting insider confidence amidst ongoing developments in the liquid biopsy sector.

ANGLE plc (OTCQX:ANPCY) has appointed Joseph Eid M.D. as Non-Executive Director, effective January 19, 2023. Dr. Eid, a certified oncologist with over 25 years of experience in clinical trials and drug development, previously held senior roles at major pharmaceutical firms including Merck and Bristol Myers Squibb. His significant contributions include leading the global strategy for Keytruda, enhancing the company’s focus on oncology biomarkers and clinical applications. Both Dr. Eid and the company aim to leverage his expertise to advance ANGLE’s liquid biopsy technology and commercial strategy.

ANGLE plc has reported a change in major holdings, as Aegon NV has crossed a voting rights threshold of 2.03% on January 6, 2023. This marks a decrease from a previous holding of 3.77%. Additionally, Aegon holds 0.25% voting rights through financial instruments, bringing the total to 2.28%. The notification to the Financial Conduct Authority (FCA) was completed on January 10, 2023. This change may indicate a shift in investor confidence or strategy regarding ANGLE plc's shares.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has appointed Juliet Thompson as a Non-Executive Director effective January 5, 2023. With extensive experience in the life sciences sector, she has advised on transactions worth over $4 billion. Thompson co-founded Code Securities and currently holds board positions at Indivior plc, Novacyt SA, and OrganOx. Both Thompson and ANGLE Chairman Garth Selvey emphasized her expertise in financing and corporate governance, which will support ANGLE's growth in the liquid biopsy market, particularly with its Parsortix system for cancer diagnostics.

ANGLE plc (OTCQX:ANPCY) announced significant business progress and an unaudited trading update for 2022, marking it as a breakthrough year with FDA clearance for its Parsortix cancer cell harvesting system. Key highlights include sensitivity and specificity results of 90% and 93%, respectively, in ovarian cancer studies. The company raised £20.1 million to support commercialization despite challenging market conditions. While 2022 revenue is anticipated just above £1 million and an operating loss of £22 million, angling for strong growth in 2023 remains a focus with a pipeline of new orders and partnerships.